Standard Donor Plasma-Stony Brook University-COVID-19

Standard Donor Plasma-Stony Brook University-COVID-19 refers to the control intervention used in a Phase 1/2 randomized controlled trial (NCT04344912) led by Stony Brook University to evaluate the safety and efficacy of convalescent plasma in hospitalized COVID-19 patients. This biologic product consists of 450-550 mL of regular blood plasma collected from healthy donors. Unlike the experimental convalescent plasma arm, this standard plasma contains low or no titers of specific anti-SARS-CoV-2 antibodies. In the trial, it served as a comparator to determine if the therapeutic benefits of convalescent plasma were specifically due to the presence of high-titer antibodies rather than the general effects of plasma transfusion, such as the replacement of clotting factors or volume expansion. The trial utilized an 80/20 randomization scheme favoring the convalescent plasma arm.

Other names

Standard Donor PlasmaStandard Plasma